Incapacitating solar urticaria: successful treatment with omalizumab

Detalhes bibliográficos
Autor(a) principal: Kieselova,Katarina
Data de Publicação: 2019
Outros Autores: Santiago,Felicidade, Henrique,Martinha
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Anais brasileiros de dermatologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300331
Resumo: Abstract: Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
id SBD-1_fc3fd45852835a283979c499eaea6eb0
oai_identifier_str oai:scielo:S0365-05962019000300331
network_acronym_str SBD-1
network_name_str Anais brasileiros de dermatologia (Online)
repository_id_str
spelling Incapacitating solar urticaria: successful treatment with omalizumabImmunoglobulin ELightPhotosensitivity disordersUrticariaAbstract: Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.Sociedade Brasileira de Dermatologia2019-05-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300331Anais Brasileiros de Dermatologia v.94 n.3 2019reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20198109info:eu-repo/semantics/openAccessKieselova,KatarinaSantiago,FelicidadeHenrique,Martinhaeng2019-07-25T00:00:00Zoai:scielo:S0365-05962019000300331Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2019-07-25T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false
dc.title.none.fl_str_mv Incapacitating solar urticaria: successful treatment with omalizumab
title Incapacitating solar urticaria: successful treatment with omalizumab
spellingShingle Incapacitating solar urticaria: successful treatment with omalizumab
Kieselova,Katarina
Immunoglobulin E
Light
Photosensitivity disorders
Urticaria
title_short Incapacitating solar urticaria: successful treatment with omalizumab
title_full Incapacitating solar urticaria: successful treatment with omalizumab
title_fullStr Incapacitating solar urticaria: successful treatment with omalizumab
title_full_unstemmed Incapacitating solar urticaria: successful treatment with omalizumab
title_sort Incapacitating solar urticaria: successful treatment with omalizumab
author Kieselova,Katarina
author_facet Kieselova,Katarina
Santiago,Felicidade
Henrique,Martinha
author_role author
author2 Santiago,Felicidade
Henrique,Martinha
author2_role author
author
dc.contributor.author.fl_str_mv Kieselova,Katarina
Santiago,Felicidade
Henrique,Martinha
dc.subject.por.fl_str_mv Immunoglobulin E
Light
Photosensitivity disorders
Urticaria
topic Immunoglobulin E
Light
Photosensitivity disorders
Urticaria
description Abstract: Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
publishDate 2019
dc.date.none.fl_str_mv 2019-05-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300331
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300331
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/abd1806-4841.20198109
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
dc.source.none.fl_str_mv Anais Brasileiros de Dermatologia v.94 n.3 2019
reponame:Anais brasileiros de dermatologia (Online)
instname:Sociedade Brasileira de Dermatologia (SBD)
instacron:SBD
instname_str Sociedade Brasileira de Dermatologia (SBD)
instacron_str SBD
institution SBD
reponame_str Anais brasileiros de dermatologia (Online)
collection Anais brasileiros de dermatologia (Online)
repository.name.fl_str_mv Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)
repository.mail.fl_str_mv abd@sbd.org.br||revista@sbd.org.br
_version_ 1752126423407001600

Registros relacionados